LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Abierto

SectorSanidad

0.45 9.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.41

Máximo

0.46

Métricas clave
By Trading Economics
Ingresos	-9.9M -48M
Ventas	1.8M 13M
Margen de beneficios	-362.728
Empleados	144
EBITDA	-10M -45M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+1347.62% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-449M 98M
Apertura anterior	-9.31
Cierre anterior	0.45

Noticias sobre sentimiento de mercado

By Acuity

79%

21%

330 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 mar 2026, 23:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mar 2026, 23:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mar 2026, 23:26 UTC

Noticias de Eventos Importantes

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mar 2026, 22:41 UTC

Charlas de Mercado

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mar 2026, 22:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:32 UTC

Charlas de Mercado

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mar 2026, 22:21 UTC

Charlas de Mercado

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mar 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 mar 2026, 22:11 UTC

Charlas de Mercado

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mar 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mar 2026, 22:06 UTC

Charlas de Mercado

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mar 2026, 22:00 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:00 UTC

Charlas de Mercado

Ganancias

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

2 mar 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

2 mar 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mar 2026, 21:34 UTC

Adquisiciones, fusiones, absorciones

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mar 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 21:17 UTC

Noticias de Eventos Importantes

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mar 2026, 20:44 UTC

Ganancias

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:43 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Treasury Yields Rise, Dollar Strengthens After Attack on Iran -- Market Talk

2 mar 2026, 20:28 UTC

Ganancias

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mar 2026, 20:25 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mar 2026, 20:24 UTC

Ganancias

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:14 UTC

Adquisiciones, fusiones, absorciones

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 20:12 UTC

Noticias de Eventos Importantes

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mar 2026, 20:08 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 20:08 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mar 2026, 20:05 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

1347.62% repunte

Estimación a 12 Meses

Media 6.08 USD 1347.62%

Máximo 15 USD

Mínimo 0.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

330 / 352 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.